Balance Sheet Details
|6 Months Ended|
Jan. 31, 2021
|Balance Sheet Related Disclosures [Abstract]|
|Balance Sheet Details||
Note 4—Balance Sheet Details
Property and Equipment
Property and equipment, net, is comprised of the following:
Depreciation and amortization expense recorded for the three and six months ended January 31, 2021 was approximately $46,000 and $96,000, respectively. Depreciation and amortization expense recorded for the three and six months ended January 31, 2020 was approximately $56,000 and $112,000, respectively.
Intangible assets, net, is comprised of the following:
In November 2020, the Company licensed generator technology for use in its clinical trials and other research and development efforts. Unless earlier terminated, the term of the license agreement will remain in effect for 85 months. The Company has determined that the license has alternative future uses in research and development projects. The value of the acquired license is recorded as an intangible asset with amortization over the estimated useful life of 85 months.
Intangible asset amortization expense recorded for the three and six months ended January 31, 2021 was approximately $12,000 and $12,000, respectively. Intangible asset expense recorded for both the three and six months ended January 31, 2020 was $0.
At January 31, 2021, the estimated amortization expense by fiscal year based on the current carrying value of intangible assets is as follows (in thousands):
Accounts Payable and Accrued Liabilities
Accounts payable and accrued liabilities are comprised of the following:
Accrued compensation is comprised of the following:
The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef